Disphar International B.V. is exploring the combination of Teysuno (S-1), a known oral chemotherapy agent, with epirubicin and oxaliplatin in patients with advanced solid tumors. The Phase 1 trial aims to establish the maximum tolerated dose (MTD) and assess safety and tolerability. Given the lack of established curative therapies for advanced solid tumors, this combination therapy could address a significant unmet medical need. The competitive landscape includes existing therapies for advanced solid tumors, but the unique oral formulation of S-1 may provide a differentiated offering. Diligence should focus on the safety profile and potential market acceptance of this combination therapy, especially in regions where oral chemotherapy is preferred.